跳转至内容
Merck
CN

SML2998

莫昔克丁

≥98% (HPLC)

别名:

Moxidectin, (6R,23E,25S)-5-O-Demethyl-28-deoxy-25-[(1E)-1,3-dimethyl-1-buten-1-yl]-6,28-epoxy-23-(methoxyimino)milbemycin B, 23-Methoxime-LL-F 28249α, CL 301,423, CL 301423, CL301,423, CL301423, Equest, ProHeart 6

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C37H53NO8
化学文摘社编号:
113507-06-5
分子量:
639.82
UNSPSC Code:
12352119
NACRES:
NA.77
MDL number:
MFCD00866560

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

莫昔克丁, ≥98% (HPLC)

InChI

1S/C37H53NO8/c1-21(2)14-25(6)33-26(7)31(38-42-8)19-36(46-33)18-29-17-28(45-36)13-12-23(4)15-22(3)10-9-11-27-20-43-34-32(39)24(5)16-30(35(40)44-29)37(27,34)41/h9-12,14,16,21-22,26,28-30,32-34,39,41H,13,15,17-20H2,1-8H3/b10-9+,23-12+,25-14+,27-11+,38-31+/t22-,26-,28+,29-,30-,32+,33+,34+,36-,37+/m0/s1

SMILES string

CO\N=C1/C[C@]2(C[C@@H]3CC(C\C=C(C)\C[C@@H](C)\C=C\C=C4/COC5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)O[C@@H]([C@H]1C)\C(C)=C\C(C)C

InChI key

YZBLFMPOMVTDJY-LSGXYNIPSA-N

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

Quality Level

100

正在寻找类似产品? 访问 产品对比指南

Biochem/physiol Actions

Moxidectin is an orally active antihelminthic (antiparasitic) that targets parasite glutamate-gated chloride ion channels (GluCls). Moxidectin binding increases target GluCl permeability, resulting in influx of chloride ions and dysfunction of the excretory pore, flaccid paralysis, and death of the parasite through host response.

pictograms

Skull and crossbonesEnvironment
GHS06,GHS09

signalword

Danger

hcodes

H301,H400

Hazard Classifications

Acute Tox. 3 Oral - Aquatic Acute 1

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000270358
0000270358
0000272732
0000272732
0000126578

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Mahmoud Sharaf et al.
Experimental parasitology, 217, 107961-107961 (2020-08-11)
Scabies is considered one of the commonest dermatological diseases that has a global health burden. Current treatment with ivermectin (IVM) is insufficient and potential drug resistance was noticed. Moxidectin (MOX), with a better pharmacological profile may be a promising alternative.
Valentin Buchter et al.
ACS infectious diseases, 7(5), 1069-1076 (2020-09-30)
Strongyloides stercoralis is a soil-transmitted helminth affecting an estimated 30-100 million people. Since the infection may be severe and life-threatening, accessible and effective treatment is pivotal. Currently, ivermectin is the drug of choice but has limitations. Moxidectin, a veterinary anthelminthic
Raj Packianathan et al.
Parasites & vectors, 13(1), 448-448 (2020-09-07)
The Australian paralysis tick, Ixodes holocyclus, causes tick paralysis in dogs and cats in the eastern coastal regions of Australia. Prevention is the best option to protect dogs against this potentially fatal disease and sarolaner provides rapid and sustained efficacy
Csilla Becskei et al.
Parasites & vectors, 13(1), 385-385 (2020-07-31)
Infection with the cardiopulmonary nematode Angiostrongylus vasorum may cause severe disease in dogs, therefore prophylactic treatments are necessary to prevent infection in dogs at risk. A clinical field study was conducted to demonstrate the efficacy and safety of an oral
Molly D Savadelis et al.
Journal of veterinary internal medicine, 34(5), 1734-1745 (2020-07-22)
Administration of moxidectin topically and doxycycline PO has been utilized experimentally as an alternative treatment for heartworm disease. However, clinical effects of this protocol remain poorly characterized. To evaluate the clinical and postmortem findings associated with administration of doxycycline and
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持